INNATE PHARMA : 2016 reference document made avail

INNATE PHARMA: 2016 REFERENCE DOCUMENT MADE AVAILABLE (IN FRENCH)

Marseille, France, April 3, 2017

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that the French version of its 2016 Reference document was filed with the Autorités des Marchés Financiers (AMF), the French stock-market authorities, on March 31 ^st , 2017, under number D.17-0282.

The 2016 Reference document is available on the Company's website www.innate-pharma.com (section Investors/Regulated information and publications/Financial reports). Hard copies are available upon request to the investor relations department of the Company.

The Registration document notably includes the following information:

• The 2016 annual financial report;
• The report by the Chairman on the conditions for preparation and organization of the work of the Supervisory Board as well as on internal control;
• The information relating to the Statutory Auditors' fees.

The English version of the 2016 Reference document will be made available on Innate Pharma's website during April 2017.

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.

Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells.

The Company's aim is to become a fully-integrated biopharmaceutical company in the area of immunotherapy and focused on serious unmet medical needs in cancer. Innate Pharma has pioneered the discovery and development of checkpoint inhibitors to activate the innate immune system. Innate Pharma's innovative approach has resulted in three first-in-class, clinical-stage antibodies targeting natural killer cell receptors that may address a broad range of solid and hematological cancer indications as well as additional preclinical product candidates and technologies. Targeting receptors involved in innate immunity also creates opportunities for the Company to develop therapies for inflammatory diseases.

The Company's expertise and understanding of natural killer cell biology have enabled it to enter into major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb and Sanofi.

Based in Marseille, France, Innate Pharma has more than 160 employees and is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com .

Information about Innate Pharma shares:

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website ( http://www.amf-france.org ) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

http://www.globenewswire.com/NewsRoom/Attachm...bc9696017b